A Randomized, Double-Blind,Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease

Trial Profile

A Randomized, Double-Blind,Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Bryostatin-1 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Neurotrope BioScience
  • Most Recent Events

    • 09 Aug 2017 According to a Neurotrope BioScience media release, the company has finalized the post hoc analyses of this trial. Based on the results of this trial a follow-on dose optimization study will be considered.
    • 19 Jul 2017 Status changed from active, no longer recruiting to completed, according to a Neurotrope BioScience media release.
    • 19 Jul 2017 According to a Neurotrope BioScience media release, the results were presented at the Alzheimer's Association International Conference 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top